SCHEMBL6286065

SCHEMBL6286065

O=C(Nc1ccc(O)cc1)Nc1ncc(C2CC2)s1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNE1 P24864 12/20 0.70
CDK2 P24941 12/20 0.70
CDK5 Q00535 12/20 0.70
SMN1; SMN2 Q16637 3/20 0.49
MEN1 O00255 2/20 0.49
MAPT P10636 2/20 0.49
RAB9A P51151 2/20 0.49
KMT2A Q03164 2/20 0.49
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49
CDK5R1 Q15078 1/20 0.47
DYRK1A Q13627 2/20 0.46
CNR1 P21554 1/20 0.45
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45
EPHX1 P07099 1/20 0.44
NPC1 O15118 1/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6282353 0.88 CCNE1 (0.68) CCNE1CDK2CDK5SMN1; SMN2MEN1
SCHEMBL6286722 0.88 CCNE1 (0.68) CCNE1CDK2CDK5SMN1; SMN2MEN1
SCHEMBL6281751 0.87 CDK2 (0.90) CCNE1CDK2CDK5SMN1; SMN2MEN1
SCHEMBL6287998 0.86 CCNE1 (0.70) CCNE1CDK2CDK5SMN1; SMN2MEN1
SCHEMBL6282688 0.84 CCNE1 (0.67) CCNE1CDK2CDK5SMN1; SMN2MEN1
SCHEMBL6288092 0.84 CCNE1 (0.64) CCNE1CDK2CDK5SMN1; SMN2MEN1
SCHEMBL6283947 0.83 CCNE1 (0.62) CCNE1CDK2CDK5SMN1; SMN2MEN1
SCHEMBL6286080 0.83 CCNE1 (0.62) CCNE1CDK2CDK5MEN1MAPT
SCHEMBL5782078 0.82 CDK2 (1.00) CCNE1CDK2CDK5SMN1; SMN2MEN1
SCHEMBL6287953 0.80 CCNE1 (0.69) CCNE1CDK2CDK5MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US claimed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US claimed
US-6863647-B2 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN S.P.A. (IT) 2005-03-08 US disclosed
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US disclosed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 CCNE1 83/4885CDK2 3/4885CDK5 129/4885
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 CCNE1 83/4885CDK2 3/4885CDK5 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.